| Paper | |
|---|---|
| (WASID) Comparison of Warfarin and Aspirin for Symptomatic Intracranial Arterial Stenosis _____ RCT comparing warfarin to aspirin 1300 mg in patients with TIA or stroke due to 50-99% stenosis of a major intracranial artery. The trial was stopped early due to significantly increased rate of death, major hemorrhage, and MI/sudden death with warfarin. There was no significant difference in the major endpoint of ischemic stroke, brain hemorrhage, or death from vascular causes other than stroke. | LINK |
| (SAMMPRIS) Stenting versus Aggressive Medical Therapy for Intracranial Arterial Stenosis _____ RCT comparing aggressive medical management to medical management + wingspan stent in patients with recent TIA or stroke secondary to 70-99% stenosis of a major intracranial artery. The trial was stopped early due to significantly higher rates of 30-day stroke or death in the stenting arm. Reduced stroke & death risk persisted in the medical arm for three years of follow up. | LINK |
| (VISSIT) Effect of a Balloon-Expandable Intracranial Stent vs Medical Therapy on Risk of Stroke in Patients with Symptomatic Intracranial Stenosis _____ RCT comparing balloon-expandable stent + medical therapy to medical therapy alone in patients with symptomatic intracranial stenosis >70%, finding a significantly increased risk of 30 day and 1 year stroke or TIA in the stenting group. This trial was stopped early after publication of SAMMPRIS data. | LINK |
| (CASSISS) Effect of Stenting Plus Medical Therapy vs Medical Therapy Alone on Risk of Stroke and Death in Patients with Symptomatic Intracranial Stenosis _____ RCT comparing medical therapy + stent to medical therapy alone in patients with TIA or nondisabling, nonperforator stroke attributed to 70-99% intracranial stenosis with stenting performed >3 weeks after the event, finding no significant difference in risk of stroke or death. | LINK |
| (WEAVE) Wingspan Stent System Post Market Surveillance (WOVEN) Wingspan One-year Vascular Events and Neurologic Outcomes _____ Postmarket surveillance trials of the wingspan stent, used in patients 22-80 with at least 2 strokes attributed to symptomatic intracranial stenosis of >70%, and at least 1 stroke while on medical therapy, finding a 2.6% periprocedural risk of stroke, bleed and death (Compared to 14.7% in SAMMPRIS, and 6.2% in NIH & US registries). At 1 year, an 8.5% stroke and death rate in stented patients was noted, including the periprocedural events. | WEAVE WOVEN |